(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Stefanie Ilgenfritz Here's what's making health news this morning: New Bid to Prevent Alzheimer's Early (WSJ): An Alzheimer's drug to be tested mostly on an extended family predisposed to the disease will mark the first large-scale trial of an experimental treatment on people who don't yet show signs of memory loss. Cardinal Health Settles With U.S. Over Pills (WSJ): The U.S. government on Tuesday settled with Cardinal Health over allegations the company distributed large quantities of addictive pain pills in Florida, backing away from a legal showdown over the pharmacy industry's responsibility for what officials call the country's deadliest drug problem. FDA Panel Backs HIV Home Test (WSJ): The mouth-swab test, made by OraSure Technologies, is sold commercially to health-care professionals to be used at facilities. If approved by the FDA, the test results could be obtained in the home like tests for pregnancy and blood sugar. Soda Makers Scramble to Fill Void as Sales Drop (NY Times): Cold, bubbly, sweet soda, long the American Champagne, is becoming product non grata in more places these days. Assisted Suicide, or Show of Love? (LA Times): With few precedents to guide them, prosecutors are left to wonder at what point assisting a suicide becomes a criminal act. Weight Loss Surgery Triggered Rare Genetic Wasting Disorder (USA Today): The death rate from the actual surgery is less than 1 percent, but complications can occur later, ranging from calcium malabsorption to the rare genetic disorder that killed a Tennessee woman. Drug Makers Continue Shift to Targeted Therapies (Dow Jones): The continuing shift away from one-size-fits-all cancer treatments will be on display this week when a medical society releases clinical data for drugs that target unique molecular features of cancer cells. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.
